Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 38-46

  Tan, Darrell H S ^a,b,c   Chan, Keith ^d   Raboud, Janet ^e,f   Cooper, Curtis ^g   Montaner, Julio S G ^d,h   Walmsley, Sharon ^a,c   Hogg, Robert S ^d,i   Klein, Marina B ^j,k   Machouf, Nima ^l   Rourke, Sean B ^b,c,e,m   Tsoukas, Chris ^j   Loutfy, Mona R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ SIMON FRASER UNIVERSITY   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k MCGILL UNIVERSITY   (Canada)

^l Clinique Medicale l'Actuel   (Canada)

^m ONTARIO HIV TREATMENT NETWORK   (Canada)

more..

Author keywords

Abacavir; Failure; Nucleoside reverse transcriptase inhibitors; Switch; Tenofovir; Virologic suppression

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NUCLEOSIDE; RITONAVIR; TENOFOVIR DISOPROXIL; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR, LAMIVUDINE DRUG COMBINATION; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VIROLOGY; ADULT; CANADA; DRUG COMBINATION; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; MALE; MIDDLE AGED; TREATMENT FAILURE; VIRUS REPLICATION;

ADENINE; ADULT; ANTI-HIV AGENTS; CANADA; COHORT STUDIES; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 80155192389     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182282cfc     Document Type: Article

References (25)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2009:1-161. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 2009.
2. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. World Health Organization; November 2009.
3. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
4. Guidelines: Clinical Management and Treatment of HIV Infected Adults in Europe. European AIDS Clinical Society; November 2009.
5. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230-2240.
6. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1: a randomized trial. Ann Intern Med. 2011;154:445-456.
7. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-1556.
8. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-1614. (Pubitemid 33063588)
9. *5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
10. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
11. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17-F24.
12. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20-28.
13. Ding X, Andraca-Carrera E, Cooper C, et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 to March 2, 2011; Boston, MA. Abstract 808.
14. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.
15. *5701 genetic testing service in Canada. Tissue Antigens. 2009;75:12-18.
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
17. Raboud JM, Loutfy MR, Su D, et al. Regional differences in rates of HIV-1 viral load monitoring in Canada: insights and implications for antiretroviral care in high income countries. BMC Infect Dis. 2010;10:40.
18. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
19. Sabin C, Worm S, Weber R, et al. Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D Study. Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA Abstract 957.
20. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-357.
21. Nicastri E, Leone S, Angeletti C, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother. 2007;60:724-732. (Pubitemid 47439674)
22. Kempf MC, Pisu M, Dumcheva A, et al. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr. 2009;52:336-341.
23. Daar E, Tierney C, Fischl M, et al. ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. Abstract 59LB.
24. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591-1601.
25. Martinez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290-297.